Compare Cipla with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs BIOCON - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA BIOCON CIPLA/
BIOCON
 
P/E (TTM) x 38.0 30.5 124.6% View Chart
P/BV x 3.9 3.9 99.6% View Chart
Dividend Yield % 0.4 0.3 164.4%  

Financials

 CIPLA   BIOCON
EQUITY SHARE DATA
    CIPLA
Mar-19
BIOCON
Mar-19
CIPLA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs678707 95.9%   
Low Rs484554 87.4%   
Sales per share (Unadj.) Rs198.291.9 215.7%  
Earnings per share (Unadj.) Rs18.516.7 110.9%  
Cash flow per share (Unadj.) Rs35.024.2 144.7%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %0.50.2 325.6%  
Book value per share (Unadj.) Rs186.3101.6 183.3%  
Shares outstanding (eoy) m805.70600.00 134.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.96.9 42.7%   
Avg P/E ratio x31.437.7 83.1%  
P/CF ratio (eoy) x16.626.1 63.7%  
Price / Book Value ratio x3.16.2 50.3%  
Dividend payout %16.26.0 270.6%   
Avg Mkt Cap Rs m468,031378,330 123.7%   
No. of employees `00022.66.1 369.3%   
Total wages/salary Rs m28,56511,653 245.1%   
Avg. sales/employee Rs Th7,053.18,994.3 78.4%   
Avg. wages/employee Rs Th1,261.51,900.7 66.4%   
Avg. net profit/employee Rs Th659.11,635.3 40.3%   
INCOME DATA
Net Sales Rs m159,71055,144 289.6%  
Other income Rs m4,7661,444 330.0%   
Total revenues Rs m164,47556,588 290.7%   
Gross profit Rs m30,97315,883 195.0%  
Depreciation Rs m13,2634,478 296.2%   
Interest Rs m1,684709 237.6%   
Profit before tax Rs m20,79112,140 171.3%   
Minority Interest Rs m-1729 -1,907.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6952,123 268.3%   
Profit after tax Rs m14,92410,026 148.9%  
Gross profit margin %19.428.8 67.3%  
Effective tax rate %27.417.5 156.6%   
Net profit margin %9.318.2 51.4%  
BALANCE SHEET DATA
Current assets Rs m124,26648,228 257.7%   
Current liabilities Rs m37,71530,376 124.2%   
Net working cap to sales %54.232.4 167.4%  
Current ratio x3.31.6 207.5%  
Inventory Days Days9168 132.7%  
Debtors Days Days9586 110.9%  
Net fixed assets Rs m105,19064,130 164.0%   
Share capital Rs m1,6113,000 53.7%   
"Free" reserves Rs m148,51157,980 256.1%   
Net worth Rs m150,12360,980 246.2%   
Long term debt Rs m38,30115,766 242.9%   
Total assets Rs m239,633121,924 196.5%  
Interest coverage x13.318.1 73.6%   
Debt to equity ratio x0.30.3 98.7%  
Sales to assets ratio x0.70.5 147.4%   
Return on assets %6.98.8 78.7%  
Return on equity %9.916.4 60.5%  
Return on capital %11.816.8 70.7%  
Exports to sales %34.728.1 123.4%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs m55,41915,506 357.4%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m57,41015,506 370.2%   
Fx outflow Rs m19,04110,399 183.1%   
Net fx Rs m38,3685,107 751.3%   
CASH FLOW
From Operations Rs m16,91111,546 146.5%  
From Investments Rs m-16,687-7,138 233.8%  
From Financial Activity Rs m-3,487-2,417 144.3%  
Net Cashflow Rs m-3,4512,103 -164.1%  

Share Holding

Indian Promoters % 16.0 40.4 39.6%  
Foreign collaborators % 20.8 20.6 101.0%  
Indian inst/Mut Fund % 12.2 8.4 145.2%  
FIIs % 23.7 10.7 221.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 19.9 131.7%  
Shareholders   161,166 109,995 146.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 7, 2020 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS